King Tigan approved
Executive Summary
King's antiemetic Tigan (trimethobenzamide) 300 mg will be the reference drug for all trimethobenzamide products following Dec. 13 NDA approval. Under an agreement with the FDA, King submitted a bioequivalence study to resolve outstanding issues (1"The Pink Sheet" Oct. 8, p. 35). King has agreed to send a "Dear Health Care Professional" letter to alert the healthcare community about the new 300 mg strength...
You may also be interested in...
King Tigan Suppository sNDA Pushed To 2004 Under Revised FDA Agreement
King has an additional two years to submit an sNDA for Tigan suppositories under an amended agreement with FDA requiring submission by December 2004
King Tigan Approval Expected In Six Months; Bioequivalence Data Submitted
King Pharmaceuticals anticipates NDA approval of the antiemetic Tigan (trimetrioberizamide) within six months, allowing time for FDA to review recently submitted clinical data.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.